Vistaseq Hereditary Cancer Panel Without BRCA
Clinical Genetic Test
Help
offered by
GTR Test Accession: Help GTR000531738.3
INHERITED DISEASEINHERITED DISEASE SUSCEPTIBILITYCANCER ... View more
Last updated in GTR: 2023-07-21
Last annual review date for the lab: 2023-07-26 LinkOut
At a Glance
Diagnosis; Pre-symptomatic; Risk Assessment
Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 3; Breast-ovarian cancer, familial, susceptibility to, 4; ...
ABRAXAS1 (4q21.23), APC (5q22.2), ATM (11q22.3), BARD1 (2q35), BMPR1A (10q23.2), ...
Molecular Genetics - Deletion/duplication analysis: Microarray; Multiplex Ligation-dependent Probe Amplification (MLPA); ...
Indviduals with family history of cancer where specific syndrome is …
Not provided
Not provided
Ordering Information
Offered by: Help
Molecular Diagnostic Laboratory
View lab's website
Specimen Source: Help
Test Order Code: Help
481240
Informed consent required: Help
Decline to answer
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
Conditions Help
Total conditions: 17
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 25
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 3
Method Category Help
Test method Help
Instrument *
Deletion/duplication analysis
Microarray
Deletion/duplication analysis
Multiplex Ligation-dependent Probe Amplification (MLPA)
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose: Help
Diagnosis; Pre-symptomatic; Risk Assessment
Target population: Help
Indviduals with family history of cancer where specific syndrome is unclear, and BRCA1 and BRCA2 testing has already been performed.
Recommended fields not provided:
Technical Information
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
The sensitivity of NGS/MPS is over 99% for the detection of single nucleotide variants, and over 85% for small/large deletions and insertions in the regions analyzed, the sensitivity of MLPA analysis is over 95% for the detection of deletions and duplications of complete exons in the regions analyzed, and the … View more
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
No
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Not provided
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.